The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CTEP 10492, a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma.
 
Malcolm David Mattes
Employment - Rutgers Cancer Institute of New Jersey
Honoraria - American Society for Radiation Oncology
Research Funding - Bristol Myers Squibb Foundation; New Jersey Health Foundation; Radiation Oncology Institute (ROI)
 
Henning Willers
No Relationships to Disclose
 
Yong Lin
No Relationships to Disclose
 
Laila A Gharzai
No Relationships to Disclose
 
Erin R. Alesi
No Relationships to Disclose
 
Christopher E Lominska
No Relationships to Disclose
 
Sung Kim
No Relationships to Disclose
 
Missak Haigentz
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Blueprint Medicines; Coherus Biosciences; Janssen; Jazz Pharmaceuticals; Takeda; Takeda
 
Varinder Kaur
Research Funding - Aspyrian Therapeutics (Inst); BeiGene (Inst); Genentech (Inst); Merck Sharp & Dohme (Inst); PDS Biotechnology (Inst); Regeneron (Inst); SDP Pharma (Inst)
 
Susanne M. Arnold
Consulting or Advisory Role - Penn State Cancer Institute
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicara Therapeutics, Inc (Inst); Ellipses Pharma (Inst); Exelixis (Inst); Fortrea Inc (Inst); Gilead Sciences (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Lilly (Inst); Lisata Therapeutics, Inc. (Inst); Merck Sharp & Dohme (Inst); National Cancer Institute (Inst); Ohio State University (Inst); Syneos Health (Inst)
 
Timothy W. Synold
No Relationships to Disclose
 
J. Silvio Gutkind
No Relationships to Disclose
 
Lori J. Wirth
Consulting or Advisory Role - Bayer; Coherus Biosciences; Curie Therapeutics; Eisai; Exelixis; Lilly; Merck; METIS Precision Medicine; Morphic Therapeutic; Tome Biosciences
Research Funding - Checkmate Pharmaceuticals (Inst); Eisai (Inst); Lilly (Inst); Novartis (Inst)
Expert Testimony - Eisai
Other Relationship - PDS Biotechnology
 
Ariella Hanker
Research Funding - Lilly
 
Rabih Said
No Relationships to Disclose
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; LTZ Therapeutics; Marengo Therapeutics; Medicenna; Merck; Navire; Pangea; Relay Therapeutics; Roche; Seagen; Tubulis GmbH; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Salma K. Jabbour
Honoraria - Advarra; IMX Medical Reviewer; Merck; Novocure; Radialogica; syntactx
Consulting or Advisory Role - AstraZeneca; AstraZeneca; BeiGene; IMX Medical Reviewer; Merck Sharp & Dohme; Syntactx
Research Funding - Beigene (Inst); Merck Sharp & Dohme (Inst); Natera (Inst); NCI (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck